Literature DB >> 24464269

Effect of crystallinity on electrostatic charging in dry powder inhaler formulations.

Jennifer Wong1, Philip Chi Lip Kwok, Tim Noakes, Ali Fathi, Fariba Dehghani, Hak-Kim Chan.   

Abstract

PURPOSE: This study aimed to characterize inherent charge generated by micron-sized drug-only formulations of amorphous and crystalline salbutamol sulfate (SS).
METHODS: Amorphous SS was produced by spray-drying whilst crystalline SS was produced by conditioning spray-dried SS with supercritical CO2 and menthol. Electrostatic charge of the powders was characterized in two ways. Firstly, the charge profile of the aerosols dispersed from an Aerolizer® was measured using a modified Electrostatic Low Pressure Impactor (ELPI™). Secondly, the net charge of the bulk powders generated from tumbling in containers composed of different materials (polyethylene, polyvinyl chloride, Teflon, nylon and stainless steel) was measured by a Faraday pail.
RESULTS: Following aerosolization, crystalline SS appeared to show more consistent charging and mass deposition than amorphous SS. In the tumbling experiment crystalline SS had a significant correlation between net charge and work function, which was absent in amorphous SS. This may be due to the long-range crystal packing which was reflected as more predictable charging. In addition, the polarity of charging was attributed to the arrangement of SS molecules in the crystal lattice.
CONCLUSIONS: The effect of crystallinity on the electrostatic charge behavior of inhalable micron-sized spherical drug particles with well-defined particle size distribution was investigated for the first time. The knowledge gained may assist in the development of optimized inhaled pharmaceutical products.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24464269     DOI: 10.1007/s11095-013-1270-6

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Investigation of triboelectric charging in dry powder inhalers using electrical low pressure impactor (ELPI).

Authors:  Martin J Telko; Jukka Kujanpää; Anthony J Hickey
Journal:  Int J Pharm       Date:  2006-12-20       Impact factor: 5.875

Review 2.  Electrostatics in pharmaceutical aerosols for inhalation.

Authors:  Jennifer Wong; Hak-Kim Chan; Philip Chi Lip Kwok
Journal:  Ther Deliv       Date:  2013-08

3.  A novel method for the production of crystalline micronised particles.

Authors:  Syed Anuar Faua'ad Syed Muhammad; Tim Langrish; Patricia Tang; Handoko Adi; Hak-Kim Chan; Sergei G Kazarian; Fariba Dehghani
Journal:  Int J Pharm       Date:  2010-01-05       Impact factor: 5.875

4.  Does electrostatic charge affect powder aerosolisation?

Authors:  Handoko Adi; Philip Chi Lip Kwok; John Crapper; Paul M Young; Daniela Traini; Hak-Kim Chan
Journal:  J Pharm Sci       Date:  2010-05       Impact factor: 3.534

Review 5.  Electrostatics of pharmaceutical inhalation aerosols.

Authors:  Philip Chi Lip Kwok; Hak-Kim Chan
Journal:  J Pharm Pharmacol       Date:  2009-12       Impact factor: 3.765

6.  Aerosol electrostatics. I: Properties of fine powders before and after aerosolization by dry powder inhalers.

Authors:  P R Byron; J Peart; J N Staniforth
Journal:  Pharm Res       Date:  1997-06       Impact factor: 4.200

7.  Effect of relative humidity on the electrostatic charge properties of dry powder inhaler aerosols.

Authors:  Philip Chi Lip Kwok; Hak-Kim Chan
Journal:  Pharm Res       Date:  2007-07-10       Impact factor: 4.200

8.  Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems.

Authors:  Paul M Young; Adrian Sung; Daniela Traini; Philip Kwok; Herbert Chiou; Hak-Kim Chan
Journal:  Pharm Res       Date:  2007-03-22       Impact factor: 4.580

  8 in total
  1 in total

1.  Effect of Relative Humidity on Bipolar Electrostatic Charge Profiles of dry Powder Aerosols.

Authors:  Jiaqi Yu; Jennifer Wong; Ari Ukkonen; Jonna Kannosto; Hak-Kim Chan
Journal:  Pharm Res       Date:  2017-05-24       Impact factor: 4.200

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.